Build Your Comparison

Side-by-side financial analysis
ACNT logo
ACNT
NVS logo
NVS
PFE logo
PFE
ZEUS logo
ZEUS
JNJ logo
JNJ
KO logo
KO
Try popular comparisons:

Stock Comparison

ACNT vs NVS vs PFE vs ZEUS vs JNJ vs KO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ACNT
Ascent Industries Co.

Steel

Basic MaterialsNASDAQ • US
Market Cap$127M
5Y Perf.+87.8%
NVS
Novartis AG

Drug Manufacturers - General

HealthcareNYSE • CH
Market Cap$292.07B
5Y Perf.+85.2%
PFE
Pfizer Inc.

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$149.09B
5Y Perf.-15.5%
ZEUS
Olympic Steel, Inc.

Steel

Basic MaterialsNASDAQ • US
Market Cap$533M
5Y Perf.+309.3%
JNJ
Johnson & Johnson

Drug Manufacturers - General

HealthcareNYSE • US
Market Cap$580.47B
5Y Perf.+71.3%
KO
The Coca-Cola Company

Beverages - Non-Alcoholic

Consumer DefensiveNYSE • US
Market Cap$355.61B
5Y Perf.+84.9%

ACNT vs NVS vs PFE vs ZEUS vs JNJ vs KO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ACNT logoACNT
NVS logoNVS
PFE logoPFE
ZEUS logoZEUS
JNJ logoJNJ
KO logoKO
IndustrySteelDrug Manufacturers - GeneralDrug Manufacturers - GeneralSteelDrug Manufacturers - GeneralBeverages - Non-Alcoholic
Market Cap$127M$292.07B$149.09B$533M$580.47B$355.61B
Revenue (TTM)$77M$56.05B$63.31B$1.90B$92.15B$49.28B
Net Income (TTM)$1M$13.53B$7.49B$14M$25.12B$13.70B
Gross Margin21.8%75.3%69.3%82.8%68.1%61.7%
Operating Margin-9.8%30.5%23.4%1.9%26.1%29.3%
Forward P/E16.9x17.5x8.9x20.7x20.8x25.3x
Total Debt$13M$37.03B$67.42B$313M$36.63B$45.49B
Cash & Equiv.$58M$11.44B$1.14B$12M$24.11B$10.27B

ACNT vs NVS vs PFE vs ZEUS vs JNJ vs KOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ACNT
NVS
PFE
ZEUS
JNJ
KO
StockJun 20Jun 26Return
Ascent Industries C… (ACNT)100187.8+87.8%
Novartis AG (NVS)100185.2+85.2%
Pfizer Inc. (PFE)10084.5-15.5%
Olympic Steel, Inc. (ZEUS)100409.3+309.3%
Johnson & Johnson (JNJ)100171.3+71.3%
The Coca-Cola Compa… (KO)100184.9+84.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: ACNT vs NVS vs PFE vs ZEUS vs JNJ vs KO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PFE and JNJ are tied at the top with 2 categories each (6-stock set) — the right choice depends on your priorities. Johnson & Johnson is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. KO and NVS also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
ACNT
Ascent Industries Co.
The Lower-Volatility Pick

Among these 6 stocks, ACNT doesn't own a clear edge in any measured category.

Best for: basic materials exposure
NVS
Novartis AG
The Growth Play

NVS is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 6.0%, EPS growth 22.5%, 3Y rev CAGR 8.0%
  • 187.2% 10Y total return vs JNJ's 142.4%
  • 6.0% revenue growth vs ACNT's -57.9%
Best for: growth exposure and long-term compounding
PFE
Pfizer Inc.
The Income Pick

PFE has the current edge in this matchup, primarily because of its strength in income & stability and defensive.

  • Dividend streak 15 yrs, beta 0.38, yield 6.6%
  • Beta 0.38, yield 6.6%, current ratio 1.16x
  • Lower P/E (8.9x vs 25.3x)
  • 6.6% yield, 15-year raise streak, vs KO's 2.5%, (1 stock pays no dividend)
Best for: income & stability and defensive
ZEUS
Olympic Steel, Inc.
The Value Pick

ZEUS is the clearest fit if your priority is valuation efficiency.

  • PEG 0.49 vs JNJ's 37.02
Best for: valuation efficiency
JNJ
Johnson & Johnson
The Defensive Pick

JNJ is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 0.01, Low D/E 51.2%, current ratio 1.11x
  • Beta 0.01 vs ZEUS's 1.23, lower leverage
  • +57.1% vs ACNT's +10.2%
Best for: sleep-well-at-night
KO
The Coca-Cola Company
The Quality Compounder

KO ranks third and is worth considering specifically for quality and efficiency.

  • 27.8% margin vs ZEUS's 0.7%
  • 13.1% ROA vs ACNT's 1.1%, ROIC 15.8% vs -6.6%
Best for: quality and efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthNVS logoNVS6.0% revenue growth vs ACNT's -57.9%
ValuePFE logoPFELower P/E (8.9x vs 25.3x)
Quality / MarginsKO logoKO27.8% margin vs ZEUS's 0.7%
Stability / SafetyJNJ logoJNJBeta 0.01 vs ZEUS's 1.23, lower leverage
DividendsPFE logoPFE6.6% yield, 15-year raise streak, vs KO's 2.5%, (1 stock pays no dividend)
Momentum (1Y)JNJ logoJNJ+57.1% vs ACNT's +10.2%
Efficiency (ROA)KO logoKO13.1% ROA vs ACNT's 1.1%, ROIC 15.8% vs -6.6%

ACNT vs NVS vs PFE vs ZEUS vs JNJ vs KO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
ACNTAscent Industries Co.
FY 2024
Stainless Steel Pipe
54.6%$97M
Specialty Chemicals
45.4%$81M
NVSNovartis AG
FY 2022
Top 20 products
74.3%$32.1B
Rest of portfolio
21.2%$9.2B
Total anti-infectives net sales
2.8%$1.2B
Anti Infectives sold under Sandoz name
1.8%$777M
PFEPfizer Inc.
FY 2025
Biopharma Segment
97.8%$61.2B
Segment Reporting, Reconciling Item, Corporate Nonsegment
2.2%$1.4B
ZEUSOlympic Steel, Inc.
FY 2024
Carbon Flat Products
57.1%$1.1B
Specialty Metals Flat Products
25.6%$497M
Tubular and Pipe Products
17.3%$336M
JNJJohnson & Johnson
FY 2024
Innovative Medicine
64.1%$57.0B
MedTech
35.9%$31.9B
KOThe Coca-Cola Company
FY 2025
Pacific
84.6%$31.6B
Bottling investments
15.4%$5.7B

ACNT vs NVS vs PFE vs ZEUS vs JNJ vs KO — Financial Metrics

Side-by-side numbers across 6 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLNVSLAGGINGJNJ

Income & Cash Flow (Last 12 Months)

Evenly matched — NVS and KO each lead in 2 of 6 comparable metrics.

JNJ is the larger business by revenue, generating $92.1B annually — 1204.2x ACNT's $77M. KO is the more profitable business, keeping 27.8% of every revenue dollar as net income compared to ZEUS's 0.7%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricACNT logoACNTAscent Industries…NVS logoNVSNovartis AGPFE logoPFEPfizer Inc.ZEUS logoZEUSOlympic Steel, In…JNJ logoJNJJohnson & JohnsonKO logoKOThe Coca-Cola Com…
RevenueTrailing 12 months$77M$56.1B$63.3B$1.9B$92.1B$49.3B
EBITDAEarnings before interest/tax-$3M$22.5B$21.0B$45M$31.4B$15.5B
Net IncomeAfter-tax profit$1M$13.5B$7.5B$14M$25.1B$13.7B
Free Cash FlowCash after capex-$7M$16.4B$9.5B$42M$19.1B$12.6B
Gross MarginGross profit ÷ Revenue+21.8%+75.3%+69.3%+82.8%+68.1%+61.7%
Operating MarginEBIT ÷ Revenue-9.8%+30.5%+23.4%+1.9%+26.1%+29.3%
Net MarginNet income ÷ Revenue+1.6%+24.1%+11.8%+0.7%+27.3%+27.8%
FCF MarginFCF ÷ Revenue-9.0%+29.2%+15.0%+2.2%+20.7%+25.5%
Rev. Growth (YoY)Latest quarter vs prior year+8.9%-0.7%+5.4%+4.4%+6.8%+12.1%
EPS Growth (YoY)Latest quarter vs prior year+8.7%-9.3%-9.5%-21.7%+91.0%+18.2%
Evenly matched — NVS and KO each lead in 2 of 6 comparable metrics.

Valuation Metrics

ZEUS leads this category, winning 4 of 7 comparable metrics.

At 19.3x trailing earnings, PFE trades at a 54% valuation discount to JNJ's 41.6x P/E. Adjusting for growth (PEG ratio), ZEUS offers better value at 0.58x vs JNJ's 37.02x — a lower PEG means you pay less per unit of expected earnings growth.

MetricACNT logoACNTAscent Industries…NVS logoNVSNovartis AGPFE logoPFEPfizer Inc.ZEUS logoZEUSOlympic Steel, In…JNJ logoJNJJohnson & JohnsonKO logoKOThe Coca-Cola Com…
Market CapShares × price$127M$292.1B$149.1B$533M$580.5B$355.6B
Enterprise ValueMkt cap + debt − cash$83M$317.7B$215.4B$834M$593.0B$390.8B
Trailing P/EPrice ÷ TTM EPS-24.22x21.29x19.27x24.29x41.60x27.18x
Forward P/EPrice ÷ next-FY EPS est.16.93x17.52x8.85x20.72x20.81x25.27x
PEG RatioP/E ÷ EPS growth rate1.39x0.58x37.02x2.43x
EV / EBITDAEnterprise value multiple14.17x10.59x10.59x20.11x26.39x
Price / SalesMarket cap ÷ Revenue1.69x5.33x2.38x0.27x6.54x7.42x
Price / BookPrice ÷ Book value/share1.56x6.43x1.72x0.97x8.19x10.40x
Price / FCFMarket cap ÷ FCF16.51x16.43x127.14x29.25x67.15x
ZEUS leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

Evenly matched — ACNT and KO each lead in 3 of 9 comparable metrics.

KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $1 for ACNT. ACNT carries lower financial leverage with a 0.15x debt-to-equity ratio, signaling a more conservative balance sheet compared to KO's 1.33x. On the Piotroski fundamental quality scale (0–9), PFE scores 7/9 vs JNJ's 5/9, reflecting strong financial health.

MetricACNT logoACNTAscent Industries…NVS logoNVSNovartis AGPFE logoPFEPfizer Inc.ZEUS logoZEUSOlympic Steel, In…JNJ logoJNJJohnson & JohnsonKO logoKOThe Coca-Cola Com…
ROE (TTM)Return on equity+1.4%+31.4%+8.3%+2.4%+31.7%+41.1%
ROA (TTM)Return on assets+1.1%+12.1%+3.6%+1.3%+13.0%+13.1%
ROICReturn on invested capital-6.6%+18.8%+7.5%+4.3%+20.7%+15.8%
ROCEReturn on capital employed-6.0%+21.1%+9.0%+5.6%+17.6%+17.3%
Piotroski ScoreFundamental quality 0–9667557
Debt / EquityFinancial leverage0.15x0.80x0.78x0.55x0.51x1.33x
Net DebtTotal debt minus cash-$44M$25.6B$66.3B$301M$12.5B$35.2B
Cash & Equiv.Liquid assets$58M$11.4B$1.1B$12M$24.1B$10.3B
Total DebtShort + long-term debt$13M$37.0B$67.4B$313M$36.6B$45.5B
Interest CoverageEBIT ÷ Interest expense13.92x4.02x2.15x48.23x10.70x
Evenly matched — ACNT and KO each lead in 3 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NVS leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in NVS five years ago would be worth $19,402 today (with dividends reinvested), compared to $8,703 for PFE. Over the past 12 months, JNJ leads with a +57.1% total return vs ACNT's +10.2%. The 3-year compound annual growth rate (CAGR) favors NVS at 20.4% vs PFE's -7.8% — a key indicator of consistent wealth creation.

MetricACNT logoACNTAscent Industries…NVS logoNVSNovartis AGPFE logoPFEPfizer Inc.ZEUS logoZEUSOlympic Steel, In…JNJ logoJNJJohnson & JohnsonKO logoKOThe Coca-Cola Com…
YTD ReturnYear-to-date-12.5%+13.9%+7.5%+9.1%+17.4%+20.3%
1-Year ReturnPast 12 months+10.2%+30.7%+12.4%+54.9%+57.1%+17.2%
3-Year ReturnCumulative with dividends+41.3%+74.4%-21.6%+5.4%+60.1%+47.0%
5-Year ReturnCumulative with dividends+25.4%+94.0%-13.0%+52.1%+60.1%+65.6%
10-Year ReturnCumulative with dividends+93.7%+187.2%+25.8%+96.3%+142.4%+121.1%
CAGR (3Y)Annualised 3-year return+12.2%+20.4%-7.8%+1.8%+17.0%+13.7%
NVS leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

KO leads this category, winning 2 of 2 comparable metrics.

KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than ZEUS's 1.23 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs ACNT's 78.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricACNT logoACNTAscent Industries…NVS logoNVSNovartis AGPFE logoPFEPfizer Inc.ZEUS logoZEUSOlympic Steel, In…JNJ logoJNJJohnson & JohnsonKO logoKOThe Coca-Cola Com…
Beta (5Y)Sensitivity to S&P 5000.47x0.45x0.38x1.23x0.01x-0.20x
52-Week HighHighest price in past year$17.92$170.46$28.75$52.65$251.71$84.04
52-Week LowLowest price in past year$11.62$112.34$23.11$27.11$149.04$65.35
% of 52W HighCurrent price vs 52-week peak+78.4%+89.8%+91.2%+90.9%+95.7%+98.3%
RSI (14)Momentum oscillator 0–10050.959.853.248.263.160.6
Avg Volume (50D)Average daily shares traded73K1.4M28.5M476.4M12.7M
KO leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PFE and JNJ and KO each lead in 1 of 2 comparable metrics.

Analyst consensus: ACNT as "Buy", NVS as "Hold", PFE as "Hold", ZEUS as "Buy", JNJ as "Buy", KO as "Buy". Consensus price targets imply 28.1% upside for ACNT (target: $18) vs -14.3% for ZEUS (target: $41). For income investors, PFE offers the higher dividend yield at 6.56% vs ZEUS's 1.20%.

MetricACNT logoACNTAscent Industries…NVS logoNVSNovartis AGPFE logoPFEPfizer Inc.ZEUS logoZEUSOlympic Steel, In…JNJ logoJNJJohnson & JohnsonKO logoKOThe Coca-Cola Com…
Analyst RatingConsensus buy/hold/sellBuyHoldHoldBuyBuyBuy
Price TargetConsensus 12-month target$18.00$170.00$26.75$41.00$251.55$86.13
# AnalystsCovering analysts4253964048
Dividend YieldAnnual dividend ÷ price+2.6%+6.6%+1.2%+2.0%+2.5%
Dividend StreakConsecutive years of raises111545656
Dividend / ShareAnnual DPS$4.02$1.72$0.57$4.87$2.04
Buyback YieldShare repurchases ÷ mkt cap+7.2%+3.2%0.0%0.0%+0.4%+0.2%
Evenly matched — PFE and JNJ and KO each lead in 1 of 2 comparable metrics.
Key Takeaway

ZEUS leads in 1 of 6 categories (Valuation Metrics). NVS leads in 1 (Total Returns). 3 tied.

Best OverallNovartis AG (NVS)Leads 1 of 6 categories
Loading custom metrics...

ACNT vs NVS vs PFE vs ZEUS vs JNJ vs KO: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ACNT or NVS or PFE or ZEUS or JNJ or KO a better buy right now?

For growth investors, Novartis AG (NVS) is the stronger pick with 6.

0% revenue growth year-over-year, versus -57. 9% for Ascent Industries Co. (ACNT). Pfizer Inc. (PFE) offers the better valuation at 19. 3x trailing P/E (8. 9x forward), making it the more compelling value choice. Analysts rate Ascent Industries Co. (ACNT) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ACNT or NVS or PFE or ZEUS or JNJ or KO?

On trailing P/E, Pfizer Inc.

(PFE) is the cheapest at 19. 3x versus Johnson & Johnson at 41. 6x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Olympic Steel, Inc. wins at 0. 49x versus Johnson & Johnson's 37. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — ACNT or NVS or PFE or ZEUS or JNJ or KO?

Over the past 5 years, Novartis AG (NVS) delivered a total return of +94.

0%, compared to -13. 0% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: NVS returned +187. 2% versus PFE's +25. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ACNT or NVS or PFE or ZEUS or JNJ or KO?

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

20β versus Olympic Steel, Inc. 's 1. 23β — meaning ZEUS is approximately -715% more volatile than KO relative to the S&P 500. On balance sheet safety, Ascent Industries Co. (ACNT) carries a lower debt/equity ratio of 15% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — ACNT or NVS or PFE or ZEUS or JNJ or KO?

By revenue growth (latest reported year), Novartis AG (NVS) is pulling ahead at 6.

0% versus -57. 9% for Ascent Industries Co. (ACNT). On earnings-per-share growth, the picture is similar: Ascent Industries Co. grew EPS 56. 7% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, NVS leads at 8. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ACNT or NVS or PFE or ZEUS or JNJ or KO?

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -7. 5% for Ascent Industries Co. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVS leads at 31. 2% versus -9. 0% for ACNT. At the gross margin level — before operating expenses — NVS leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ACNT or NVS or PFE or ZEUS or JNJ or KO more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Olympic Steel, Inc. (ZEUS) is the more undervalued stock at a PEG of 0. 49x versus Johnson & Johnson's 37. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Pfizer Inc. (PFE) trades at 8. 9x forward P/E versus 25. 3x for The Coca-Cola Company — 16. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACNT: 28. 1% to $18. 00.

08

Which pays a better dividend — ACNT or NVS or PFE or ZEUS or JNJ or KO?

In this comparison, PFE (6.

6% yield), NVS (2. 6% yield), KO (2. 5% yield), JNJ (2. 0% yield), ZEUS (1. 2% yield) pay a dividend. ACNT does not pay a meaningful dividend and should not be held primarily for income.

09

Is ACNT or NVS or PFE or ZEUS or JNJ or KO better for a retirement portfolio?

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

20), 2. 5% yield, +121. 1% 10Y return). Both have compounded well over 10 years (KO: +121. 1%, ZEUS: +96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ACNT and NVS and PFE and ZEUS and JNJ and KO?

These companies operate in different sectors (ACNT (Basic Materials) and NVS (Healthcare) and PFE (Healthcare) and ZEUS (Basic Materials) and JNJ (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ACNT is a small-cap quality compounder stock; NVS is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock; ZEUS is a small-cap quality compounder stock; JNJ is a large-cap quality compounder stock; KO is a large-cap quality compounder stock. NVS, PFE, ZEUS, JNJ, KO pay a dividend while ACNT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.